A Randomized, Double Blind, Multicenter, Phase 3 Study of Efficacy, Safety, and Tolerability of Brincidofovir vs Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV-Seropositive Kidney Transplant Recipients who Recieved Antilymphocyte Indu

Grants and Contracts Details

StatusFinished
Effective start/end date7/25/169/6/16

Funding

  • Chimerix Incorporated: $6,052.00